Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yvonne Füll
Observed name:
Füll, Yvonne
Institutions:
Universitätsklinikum Tübingen,
University of Tübingen
Observed institutions:
Universitätsklinikum Tübingen,
Nabriva Therapeutics (Austria),
Hertie Institute for Clinical Brain Research,
Xilio Therapeutics (United States),
University of Tübingen
ORCID:
0000-0003-2290-2366
Observed ORCID:
0000-0003-2290-2366
OpenAlex ID:
A5017251185
Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA
2024
·
Philipp Reautschnig
, Carolin Fruhner
, et al.
·
Nature Biotechnology
·
65
An improved SNAP-ADAR tool enables efficient RNA base editing to interfere with post-translational protein modification
2024
·
Karthika Devi Kiran Kumar
, Shubhangi Singh
, et al.
·
Nature Communications
·
25
Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
2022
·
Julia Koch-Heier
, Annika Schönsiegel
, et al.
·
Frontiers in Pharmacology
·
15
PDF
Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients
2025
·
Yvonne Füll
, Lara Maria Schüssele
, et al.
·
Frontiers in Immunology
·
8
PDF
MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection
2024
·
Julia Koch-Heier
, Annette B. Vogel
, et al.
·
Frontiers in Immunology
·
8
A conserved threonine in the S1–S2 loop of KV7.2 and KV7.3 channels regulates voltage-dependent activation
2012
·
Yvonne Füll
, Guiscard Seebohm
, et al.
·
Pflügers Archiv - European Journal of Physiology
·
7
Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats
2022
·
Yvonne Füll
, Christian Wallasch
, et al.
·
Frontiers in Pharmacology
·
6
Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients
2025
·
Hamza, Hazem
, Hoffmann, Helen
, et al.
·
Universitätsbibliothek Tübingen
·
1
Funktionelle Auswirkungen Epilepsie-assoziierter Kaliumkanalmutationen
2013
·
Yvonne Füll
·
1
Safety, tolerability, pharmacokinetics, and pharmacodynamics of zapnometinib: results from a phase I clinical study
2026
·
Stephan Stenglein
, Julian Volk
, et al.
·
Frontiers in Pharmacology
PDF
In vivo antiviral efficacy and immune dampening effect of zapnometinib emphasize a dual therapeutic potential against COVID-19
2022
·
Yvonne Füll
, Lara Waidele
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
11
Citation count:
136
H-index:
6
I10-index:
3
Year
Topic
Type